HGS |
HGS-ETR1 (anti-TRAIL-Rl mAb) |
Phase II completed: NHL, colorectal cancer, NSCLC |
HGS-ETR1 + Paclitaxel + Carboplatin |
Phase Ib: advanced solid tumors |
HGS-ETR1 + Gemcitabine + Cisplatin |
Phase Ib: advanced solid tumors |
HGS-ETR1 + Bortezomib |
Phase II: advanced multiple myeloma |
HGS-ETR2 (anti-TRAIL-R2 mAb) |
Phase I: advanced solid tumors |
HGS-ETR2 + Chemotherapy |
Phase Ib: advanced solid tumors |
HGS-TR2J (anti-TRAIL-R2 mAb) |
Phase I: advanced solid tumors |
Daiichi Sankyo Inc. |
TRA-8 (anti-TRAIL-R2) |
Phase I: advanced solid tumors and lymphomas |
CS-1008 (humanized version of TRA-8) |
Phase I |
Novartis |
LBY135 (anti-TRAIL-R2) |
Phase I/II: advanced solid tumors |
LBY135 + Capecitabine |
Phase I/II: advanced solid tumors (recruiting since 2006) |
Genentech |
Apomab (anti-TRAIL-R2) |
Phase I/II: advanced solid tumors |
Apomab + Avastin |
Phase II: advanced solid tumors (initiated in 2007) |
Amgen |
AMG655 (anti-TRAIL-R2) |
Phase I: NSCLC, colorectal cancer (initiated in 2005) |
Genentech/Amgen |
Apo2L/TRAlL (soluble) |
Phase Ib |
Apo2L/TRAIL + Rituximab |
Phase Ib/II: NHL (recruiting since 2006) |
Ad5-TRAIL |
Phase Ia: organ-confined prostate cancer |